基于基础实验室和临床参数诊断精氨酸加压素缺乏症(中枢性尿崩症)或原发性多饮的新型诊断评分:两项国际多中心前瞻性诊断研究结果
研究基于两项国际多中心前瞻性诊断研究,纳入299例接受高渗盐水试验的患者,开发并验证了结合基础实验室指标、症状和病史的诊断评分。在验证队列中,评分诊断精氨酸加压素缺乏症的AUC为91%, cutoff >441分时准确率86%,高特异性cutoff <415分和>461分均具93%特异性。逐步诊断法使75%患者得以诊断。
要点
- 基础血浆钠>145 mmol/L可100%特异诊断精氨酸加压素缺乏症。
- 临床评分AUC 91%,cutoff >441分诊断准确率86%。
- 逐步诊断法使223/299(75%)患者获诊断。
核心结论
- 提出逐步诊断法:先基础实验室检查,用rule-in和rule-out标准即时治疗,中间病例用新评分高准确度识别精氨酸加压素缺乏症或原发性多饮,可能缩短诊断时间并减少对刺激或动态试验的依赖。
研究设计与样本
- 数据来自两项国际多中心前瞻性诊断研究:CODDI为非随机对照诊断性国际多中心非劣效研究,在瑞士、德国、巴西11个三级医疗中心进行;CARGOx为随机对照交叉诊断性国际多中心非劣效研究,在瑞士、德国、荷兰、意大利、英国、巴西7个三级医疗中心进行。
- 纳入成人多饮(>3 L/天)和低渗性多尿(24小时>50 mL/kg体重且尿渗透压<800 mOsm/kg)患者及既往诊断精氨酸加压素缺乏症成人患者。
- 共299例患者纳入分析,发育队列141例(59例[42%]精氨酸加压素缺乏症,82例[58%]原发性多饮),验证队列158例(69例[44%]精氨酸加压素缺乏症,89例[56%]原发性多饮)。
主要发现
- 验证队列中,基础血浆钠>145 mmol/L诊断精氨酸加压素缺乏症特异性100%(95%CI 61-100);钠<135 mmol/L诊断原发性多饮特异性100%(34-100);和肽素>5.6 pmol/L诊断原发性多饮特异性100%(74-100)。
- 验证队列中,临床评分AUC为91%(87-96),cutoff >441分诊断精氨酸加压素缺乏症总体准确率86%(80-91)。
- 验证队列中,高特异性cutoff <415分诊断原发性多饮特异性93%(87-99),高特异性cutoff >461分诊断精氨酸加压素缺乏症特异性93%(88-98)。
- 逐步诊断法使299例中223例(75%)患者得以诊断。
关键数值与推荐
- 最终评分包括:基础血浆钠乘以血浆渗透压除以100;血浆和肽素>4.9 pmol/L计-50分;夜尿≥3次/晚计+30分或夜尿2次/晚计+20分;多尿或多饮突然起病计+20分;每晚饮水量>1 L计+30分;垂体前叶功能障碍计+50分;垂体手术史计+50分。
- 验证队列中,高特异性cutoff <415分诊断原发性多饮特异性93%(87-99),高特异性cutoff >461分诊断精氨酸加压素缺乏症特异性93%(88-98)。
临床怎么用
- 作者提出逐步诊断法:从基础实验室检查开始,使用rule-in和rule-out标准可即时治疗;对中间病例,新型评分有助于高准确度识别精氨酸加压素缺乏症或原发性多饮。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Distinguishing arginine vasopressin deficiency (central diabetes insipidus) from primary polydipsia is challenging. There is no validated initial laboratory assessment or diagnostic score to rule-in or rule-out arginine vasopressin deficiency during the first consultation. Therefore, this study aimed to evaluate the diagnostic potential of basal laboratory parameters and to develop a practical diagnostic score. METHODS: Data from two international multicentre studies of patients with arginine vasopressin deficiency and primary polydipsia undergoing the hypertonic saline test were used to evaluate the diagnostic potential of basal laboratory tests and to develop a score incorporating laboratory results, symptoms, and medical history. CODDI was a non-randomised, controlled, diagnostic, international, multicentre non-inferiority study in 11 tertiary medical centres in Switzerland, Germany, and Brazil. CARGOx was a randomised, controlled, cross-over, diagnostic, international, multicentre non-inferiority study across seven tertiary medical centres in Switzerland, Germany, the Netherlands, Italy, the UK, and Brazil. Participants were adult patients with polydipsia (>3 L per day) and hypotonic polyuria (>50 mL/kg bodyweight in 24 h and urine osmolality <800 mOsm/kg) and adult patients with a previous diagnosis of arginine vasopressin deficiency. Data were derived from the initial consultation and a basal laboratory test. For each laboratory parameter, the cutoffs resulting in the highest specificity at 100% sensitivity and the highest sensitivity at 100% specificity were identified. For the diagnostic score, the overall best cutoff, high-sensitivity cutoff (≥95% sensitivity), and high-specificity cutoff (≥95% specificity) were identified. Each cutoff was derived from the first study (development), and their performance was determined in the second study (validation). The final score included the sum of: basal plasma sodium multiplied by plasma osmolality, divided by 100; -50 points for plasma copeptin more than 4·9 pmol/L; +30 points for nycturia (≥3 times per night) or +20 points for nycturia (2 times per night); +20 points for sudden polyuria or polydipsia onset; +30 points for drinking more than 1 L per night; +50 points for anterior pituitary dysfunction and +50 points for pituitary surgery history. The diagnostic performance in predicting arginine vasopressin deficiency was examined by the receiver operating characteristic (ROC) area under the curve (AUC) and by sensitivity and specificity. The studies were registered with ClinicalTrials.gov (NCT01940614 and NCT03572166). FINDINGS: 299 patients who underwent the hypertonic saline test from July 1, 2013, to Sept 30, 2022 were included in this analysis. 141 patients were in the development cohort (59 [42%] had arginine vasopressin deficiency; 82 [58%] had primary polydipsia) and 158 patients were in the validation cohort (69 [44%] had arginine vasopressin deficiency; 89 [56%] had primary polydipsia). In the development cohort, the median age of patients with arginine vasopressin deficiency was 45 years (IQR 33-53), with 38 (64%) of 59 being female and 21 (36%) male, compared with a median age of 32 years (IQR 24-44) and 55 (67%) of 82 being female and 27 (33%) male in the group of patients with primary polydipsia. In the validation cohort, patients with arginine vasopressin deficiency had a median age of 42 years (IQR 32-54), with 38 (55%) of 69 being female and 31 (45%) male, compared with a median age of 37 years (IQR 28-50) and 68 (76%) of 89 being female and 21 (24%) male for patients with primary polydipsia. In the validation cohort, basal plasma sodium of more than 145 mmol/L identified arginine vasopressin deficiency with 100% specificity (95% CI 61-100), whereas primary polydipsia was identified by sodium less than 135 mmol/L with 100% specificity (34-100) and by copeptin more than 5·6 pmol/L with 100% specificity (74-100). In the validation cohort, the clinical score had an AUC of 91% (87-96), a cutoff of more than 441 points provided an overall accuracy of 86% (80-91) for diagnosing arginine vasopressin deficiency. In the validation cohort, the high-specificity cutoff of less than 415 points had 93% specificity (87-99) for diagnosing primary polydipsia, and the high-specificity cutoff of more than 461 points had 93% specificity (88-98) for diagnosing arginine vasopressin deficiency. This stepwise approach enabled diagnosis in 223 (75%) of 299 patients. INTERPRETATION: We introduce a stepwise diagnostic approach, starting with basal laboratory tests and rule-in and rule-out criteria for immediate treatment. For intermediate cases, the novel score aids in identifying arginine vasopressin deficiency or primary polydipsia with high accuracy. This approach could lead to shortening the diagnostic timeline and reducing dependence on stimulation or dynamic tests. FUNDING: Swiss National Science Foundation. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.
引用
- Atila C, Chifu I, Drummond JB, et al. A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international multicentre prospective diagnostic studies. Lancet Diabetes Endocrinol. 2025. PMID: 40294614. doi:10.1016/S2213-8587(25)00053-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。